SkinHealth Systems Inc. (SKIN) reported $72.1 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 7.8%. EPS of -$0.02 for the same period compares to $0.03 a year ago.
The reported revenue represents a surprise of -1.96% over the Zacks Consensus Estimate of $73.54 million. With the consensus EPS estimate being -$0.04, the EPS surprise was +50%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how SkinHealth Systems Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- Americas: $49.9 million compared to the $51.05 million average estimate based on two analysts. The reported number represents a change of -4% year over year. Geographic Revenue- EMEA: $14.9 million compared to the $17.91 million average estimate based on two analysts. The reported number represents a change of -19% year over year. Geographic Revenue- Asia Pacific (APAC): $7.3 million compared to the $6.78 million average estimate based on two analysts. The reported number represents a change of -5.2% year over year. Delivery Systems Net Sales: $18.3 million compared to the $19.72 million average estimate based on two analysts. The reported number represents a change of -18.3% year over year. Consumables Net Sales: $53.9 million compared to the $54.06 million average estimate based on two analysts. The reported number represents a change of -3.4% year over year.View all Key Company Metrics for SkinHealth Systems Inc. here>>>
Shares of SkinHealth Systems Inc. have returned -32.8% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SkinHealth Systems Inc. (SKIN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).